Final Clinical Results With Laboratory Correlates In The Phase I Trial Of Lenalidomide Plus Plerixafor In Previously Treated Chronic Lymphocytic Leukemia (Cll)

Introduction: Lenalidomide is an immunomodulatory small molecule with efficacy in CLL, though monotherapy responses are typically partial and delayed. Plerixafor, a small molecule inhibitor of the CXCR4 receptor responsible for homing CLL to the microenvironment, has been safely utilized in CLL. The combination of plerixafor with lenalidomide offered a novel non-cytotoxic alternative to improve anti-tumor activity through targeting of the essential pro-survival microenvironment.